This is not true. Many companies that appeared to have been completely run, trying to do exactly the same thing, have failed catastrophically. Assuming this gets to validation, which depends on the technology, and the trial and the skill managing all of it, then the fact that they thought through the production issues ahead of time, in a manner that will further make the product affordable to produce and deliver, successfully, this will have been a huge accomplishment and success beyond what most other companies could dream of achieving. <br /> <br /> We’re along for the ride. It is not meeting everyone’s timeline for “retirement”. I get it. There are opportunity costs for choosing this ride instead of another. But those choices are the shareholder’s choices. One could trade in and out quite profitably, and choose to bet on any number of other established biotechs with revenues and products. If investors are here and holding, it can’t be that they are incompetent, it might be that the entire process of validation is incredibly long and frustrating for breakthrough biomedical products like this, but it’s not that they are incompetent fools. If it fails even, personally, I would say it was a skillfully run effort, regardless of the complaints some might have.